Duration of Dengue Viremia in Blood Donors and Relationships Between Donor Viremia, Infection Incidence and Clinical Case Reports During a Large Epidemic

Busch, Michael P.; Sabino, Éster Cerdeira; Brambilla, Donald; Lopes, Maria Esther; Capuani, Ligia; Chowdhury, Dhuly; McClure, Christopher; Linnen, Jeffrey M.; Prince, Harry E.; Simmons, Graham; Lee, Tzong‐Hae; Kleinman, Steven; Custer, Brian

doi:10.1093/infdis/jiw122

Cited by 57 publications

(58 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, ZIKV and DENV neutralization tests were performed on follow‐up samples from IgM positive individuals using reporter virus particles (RVP; Integral Molecular). These assays involve parallel titration of donor serum on RVPs bearing the structural proteins of ZIKV and the four DENVs, as previously described …”

Section: Methodsmentioning

confidence: 99%

First cases of Zika virus–infected US blood donors outside states with areas of active transmission

Williamson¹,

Linnen

Kessler

et al. 2017

Transfusion

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

First cases of Zika virus–infected US blood donors outside states with areas of active transmission

Williamson¹,

Linnen

Kessler

et al. 2017

Transfusion

Self Cite

View full text Add to dashboard Cite

show abstract

“…Surprisingly, NAT has detected only five DENV positive donations since its introduction in blood screening in FP in 2013, accounting for a rate of 0·018% which is 30 times lower than what was reported in Brazil in 2012 . Mini pool NAT impairs the sensitivity of the screening and hence could have underestimated the number of positive donations as it was reported that the DENV RNA loads in blood donors are not very high (median 2·3–3·5 log copies/ml) . However, in contrast to Brazil, which was experiencing an epidemic during the study period, the circulation of DENV in FP over the past four years was low as suggested by the high prevalence (80%) of anti‐DENV antibodies in the FP adult population explaining the low NAT yield .…”

Section: Discussionmentioning

confidence: 74%

Section: Discussionmentioning

confidence: 90%

Transfusion risk associated with recent arbovirus outbreaks in French Polynesia

et al. 2019

View full text Add to dashboard Cite

Background and objectives French Polynesia, where dengue virus (DENV) has been present for a long time, experienced two successive outbreaks of Zika (ZIKV) and chikungunya viruses (CHIKV) between 2013 and 2015. To avoid the transmission of these viruses by transfusion, nucleic acid testing (NAT) has been in place for DENV since 2013 and for ZIKV and CHIKV during epidemics. The objective was to compare the estimated risk of viraemic blood donation with NAT results and to discuss the impact on the prevention of transfusion‐related infectious risk. Materials and methods The average risks of viraemic blood donation were estimated per year for DENV, and during the epidemic periods for ZIKV and CHIKV, using the Biggerstaff and Petersen model based on the incidence rate, the mean length of viraemia and the frequency of asymptomatic infection. The estimated risks were compared with the number of viraemic blood donations detected by NAT. Results According to the different assumptions, risks estimates ranged from 11·2 to 53·1/100 000 donations for DENV, 746 to 1924/100 000 for ZIKV and 1083 /100 000 for CHIKV. When compared to the number of donations collected during the study periods, these estimates match NAT results (5 blood donors reactive for DENV, 42 for ZIKV and 34 for CHIKV). Conclusion The risks of viraemic blood donation were related to the viral incidence in the general population and concordant with NAT results. These findings suggest that the screening may be optimized by a targeted NAT implementation based on incidence data.

show abstract

“…There is limited knowledge about the magnitude of viremia in RRV‐infected individuals, and there is no understanding of a threshold quantity of infectious RRV particles required for transfusion transmission. Investigating these paucities in our understanding could involve large‐scale donor‐recipient clinical studies, similar to those performed previously for other arboviruses . Mouse studies suggest that viremia is at its highest 1 day after infection (23,820 copies/µL), persisting for 5 days in most cases (average, 37 copies/µL), but can be extended to 9 days at a low viral load (6 copies/µL) in some individuals .…”

Section: Discussionmentioning

confidence: 94%

Ross River virus in Australian blood donors: possible implications for blood transfusion safety

et al. 2018

View full text Add to dashboard Cite

Our results suggest that the yearly risk of collecting a RRV-infected blood donation in Australia is low and is at the lower range of previous risk modeling. The majority of Australian donor centers were not in areas known to be at the highest risk for RRV transmission, which was not taken into account in previous models based on notification data. Therefore, we believe that the risk of RRV transfusion transmission in Australia is acceptably low and appropriately managed through existing risk management, including donation restrictions and recall policies.

show abstract

Duration of Dengue Viremia in Blood Donors and Relationships Between Donor Viremia, Infection Incidence and Clinical Case Reports During a Large Epidemic

Abstract: These parameters allow projections of dengue incidence from donor NAT yield data and vice versa, and suggest that viremic donations will be rare relative to clinical disease cases.

Cited by 57 publications

References 34 publications

First cases of Zika virus–infected US blood donors outside states with areas of active transmission

First cases of Zika virus–infected US blood donors outside states with areas of active transmission

Transfusion risk associated with recent arbovirus outbreaks in French Polynesia

Ross River virus in Australian blood donors: possible implications for blood transfusion safety

Contact Info

Product

Resources

About